Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 08, 2015
Amneal Introduces Generic Lidocaine 5% Ointment
PDF format download (opens in new window)
Nov 25, 2015
Impax Receives European Commission Marketing Authorization for NUMIENT™ (Levodopa and Carbidopa) Modified-Release Capsules for the Symptomatic Treatment of Adult Patients with Parkinson's Disease
PDF format download (opens in new window)
Nov 24, 2015
Impax Launches Generic Version of Avodart® (Dutasteride) Capsules, 0.5 mg
PDF format download (opens in new window)
Nov 09, 2015
Impax Reports Third Quarter 2015 Financial Results
PDF format download (opens in new window)
Nov 05, 2015
Impax to Present at the 24th Annual Credit Suisse Healthcare Conference
PDF format download (opens in new window)
Oct 22, 2015
Amneal Pharmaceuticals named Company of the Year, Americas
PDF format download (opens in new window)
Oct 21, 2015
Impax Receives FDA Approval for Generic Version of Intuniv® (Guanfacine) Extended-Release Tablets, 1 mg, 2 mg, 3 mg and 4 mg
PDF format download (opens in new window)
Oct 09, 2015
Impax to Report Third Quarter 2015 Results on November 9, 2015
PDF format download (opens in new window)
Oct 08, 2015
Janet S. Vergis Appointed to Impax Laboratories Board of Directors
PDF format download (opens in new window)
Oct 05, 2015
Impax Receives FDA Approval for Generic Version of DIABETA® (Glyburide) Tablets, USP, 1.25 mg, 2.5 mg, and 5 mg
PDF format download (opens in new window)
Sep 25, 2015
Impax Receives Positive CHMP Opinion for NUMIENT™ (Levodopa and Carbidopa) Modified-Release Capsules for the Symptomatic Treatment of Adult Patients with Parkinson's disease
PDF format download (opens in new window)
Sep 22, 2015
Impax Receives FDA Approval for Generic Version of Testred® C-III (Methyltestosterone Capsules, USP), 10 mg
PDF format download (opens in new window)
Sep 17, 2015
Impax Receives FDA Approval for Generic Version of Mestinon® Timespan® Tablets, 180 mg
PDF format download (opens in new window)
Sep 11, 2015
Impax to Present at the Morgan Stanley Global Healthcare Conference
PDF format download (opens in new window)
Sep 08, 2015
Impax Announces Resolution of FDA Warning Letter Related to its Hayward Manufacturing Facility
PDF format download (opens in new window)
Aug 25, 2015
Amneal Announces New Biosciences Unit with Charles Lucarelli as President
PDF format download (opens in new window)
Aug 18, 2015
Amneal Launches Aripiprazole Oral Solution
PDF format download (opens in new window)
Aug 10, 2015
Impax Reports Second Quarter 2015 Financial Results
PDF format download (opens in new window)
Aug 10, 2015
Impax Announces Sale of Daraprim® to Turing Pharmaceuticals AG
PDF format download (opens in new window)
Jul 31, 2015
Amneal Makes Strategic Investment in Ireland
PDF format download (opens in new window)
Jul 17, 2015
Amneal Adds Four New Products to its Growing Portfolio
PDF format download (opens in new window)
Jul 06, 2015
Impax to Report Second Quarter 2015 Results on August 10, 2015
PDF format download (opens in new window)
Jul 06, 2015
Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors
PDF format download (opens in new window)
Jun 25, 2015
Impax Laboratories, Inc. Prices Private Offering of Convertible Senior Notes
PDF format download (opens in new window)
Jun 24, 2015
Impax Laboratories, Inc. Announces Private Offering of Convertible Senior Notes
PDF format download (opens in new window)
Jun 16, 2015
FDA Approves ZOMIG® (zolmitriptan) Nasal Spray for Migraine in Pediatric Patients (Ages 12-17)
PDF format download (opens in new window)
Jun 04, 2015
Impax to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
May 14, 2015
Impax to Present at the UBS 2015 Global Healthcare Conference
May 11, 2015
FDA Performs GMP and Pre-Approval Inspections of Impax's Hayward Facility
May 11, 2015
Impax Reports First Quarter 2015 Financial Results
May 08, 2015
Impax to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
May 04, 2015
Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance
May 01, 2015
Amneal Closes Deal to Acquire the Generic Business of Actavis Australia
PDF format download (opens in new window)
Apr 16, 2015
Impax to Report First Quarter 2015 Results on May 11, 2015
Mar 30, 2015
Amneal Signs Deal to Acquire the Generic Business of Actavis Australia
PDF format download (opens in new window)
Mar 10, 2015
Impax Completes Acquisition Of Tower Holdings, Inc. And Lineage Therapeutics Inc.
Feb 25, 2015
Impax to Present at the Cowen and Company 35th Annual Health Care Conference
Feb 24, 2015
Impax Revenues Increased 30% to $131 Million in Fourth Quarter 2014
Jan 29, 2015
Impax to Report Fourth Quarter 2014 Results on February 24, 2015
Jan 26, 2015
Impax Receives FDA Approval for a Generic Version of Lamictal® Orally Disintegrating Tablets (ODT)
Jan 08, 2015
Impax Pharmaceuticals Announce FDA Approval of RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules for the Treatment of Parkinson's disease
Jan 07, 2015
Amneal to Present at Conference
PDF format download (opens in new window)
Jan 06, 2015
Impax to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top